Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives
作者： Nele Boeckx , Ken Op de Beeck , Vanessa Deschoolmeester , Guy Van Camp , Patrick Pauwels
DOI: 10.1007/S11888-014-0242-5
关键词: In patient 、 KRAS 、 PTEN 、 Circulating tumor cell 、 Tumor heterogeneity 、 Oncology 、 Colorectal cancer 、 Colorectal surgery 、 Neuroblastoma RAS viral oncogene homolog 、 Internal medicine 、 Medicine
摘要: Anti-EGFR therapy in metastatic colorectal cancer (mCRC) has improved survival outcome. However, many patients do not respond to this and almost all develop resistance after a few months of treatment. Since 2008, the been restricted without mutations KRAS, an important target EGFR pathway, as these benefit from anti-EGFR therapy. Recently, changed all-RAS wild-type strategy. Despite restrictions, still 40 60 % mCRC are resistant. New biomarkers need be identified order improve patient selection. Another problem is tumor heterogeneity, which impedes detection genes can consequently lead wrong treatment decisions. A possible solution for may found liquid biopsies. In review, known promising upcoming associated with will summarized. Moreover, potential added value biopsies selection follow-up discussed.
springer.com
sci-hub.se 参考文章(116)
Eric Van Cutsem, Claus-Henning Köhne, István Láng, Gunnar Folprecht, Marek P. Nowacki, Stefano Cascinu, Igor Shchepotin, Joan Maurel, David Cunningham, Sabine Tejpar, Michael Schlichting, Angela Zubel, Ilhan Celik, Philippe Rougier, Fortunato Ciardiello, Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status Journal of Clinical Oncology. ,vol. 29, pp. 2011- 2019 ,(2011) , 10.1200/JCO.2010.33.5091
Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent-Puig, Frédérique Penault-Llorca, Philippe Rougier, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Federico Cappuzzo, Milo Frattini, Francesca Molinari, Piercarlo Saletti, Sara De Dosso, Miriam Martini, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi, Josep Tabernero, Teresa Macarulla, Frédéric Di Fiore, Alice Oden Gangloff, Fortunato Ciardiello, Per Pfeiffer, Camilla Qvortrup, Tine Plato Hansen, Eric Van Cutsem, Hubert Piessevaux, Diether Lambrechts, Mauro Delorenzi, Sabine Tejpar, None, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncology. ,vol. 11, pp. 753- 762 ,(2010) , 10.1016/S1470-2045(10)70130-3
Alain R Thierry, Florent Mouliere, Safia El Messaoudi, Caroline Mollevi, Evelyne Lopez-Crapez, Fanny Rolet, Brigitte Gillet, Celine Gongora, Pierre Dechelotte, Bruno Robert, Maguy Del Rio, Pierre-Jean Lamy, Frederic Bibeau, Michelle Nouaille, Virginie Loriot, Anne-Sophie Jarrousse, Franck Molina, Muriel Mathonnet, Denis Pezet, Marc Ychou, Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Nature Medicine. ,vol. 20, pp. 430- 435 ,(2014) , 10.1038/NM.3511
S.-H. Lee, B.-K. Ahn, S.-U. Baek, H.-K. Chang, BRAF mutation in multiple primary cancer with colorectal cancer and stomach cancer Gastroenterology Report. ,vol. 1, pp. 70- 74 ,(2013) , 10.1093/GASTRO/GOT004
C. Bokemeyer, I. Bondarenko, J.T. Hartmann, F. de Braud, G. Schuch, A. Zubel, I. Celik, M. Schlichting, P. Koralewski, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Annals of Oncology. ,vol. 22, pp. 1535- 1546 ,(2011) , 10.1093/ANNONC/MDQ632
Sarah-Jane Dawson, Dana WY Tsui, Muhammed Murtaza, Heather Biggs, Oscar M Rueda, Suet-Feung Chin, Mark J Dunning, Davina Gale, Tim Forshew, Betania Mahler-Araujo, Sabrina Rajan, Sean Humphray, Jennifer Becq, David Halsall, Matthew Wallis, David Bentley, Carlos Caldas, Nitzan Rosenfeld, None, Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer The New England Journal of Medicine. ,vol. 368, pp. 1199- 1209 ,(2013) , 10.1056/NEJMOA1213261
Sabine Tejpar, Ilhan Celik, Michael Schlichting, Ute Sartorius, Carsten Bokemeyer, Eric Van Cutsem, Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab Journal of Clinical Oncology. ,vol. 30, pp. 3570- 3577 ,(2012) , 10.1200/JCO.2012.42.2592
David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype, Ian Chau, Eric Van Cutsem, None, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 337- 345 ,(2004) , 10.1056/NEJMOA033025
Carsten Bokemeyer, Igor Bondarenko, Anatoly Makhson, Joerg T. Hartmann, Jorge Aparicio, Filippo de Braud, Serban Donea, Heinz Ludwig, Gunter Schuch, Christopher Stroh, Anja H. Loos, Angela Zubel, Piotr Koralewski, Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 663- 671 ,(2009) , 10.1200/JCO.2008.20.8397
Timothy S Maughan, Richard A Adams, Christopher G Smith, Angela M Meade, Matthew T Seymour, Richard H Wilson, Shelley Idziaszczyk, Rebecca Harris, David Fisher, Sarah L Kenny, Edward Kay, Jenna K Mitchell, Ayman Madi, Bharat Jasani, Michelle D James, John Bridgewater, M John Kennedy, Bart Claes, Diether Lambrechts, Richard Kaplan, Jeremy P Cheadle, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial The Lancet. ,vol. 377, pp. 2103- 2114 ,(2011) , 10.1016/S0140-6736(11)60613-2